Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487786 · ClinicalTrials.gov registry record · Phase 1
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
A Phase 1 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00487786 is a Phase 1 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 64 participants.
The verdict
NCT00487786, a Phase 1 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist. OGX-427 is an antisense product that inhibits expression of one of the heat shock proteins. Decreasing this heat shock protein (Hsp27) should result in down regulation of pathways implicated in cancer progression and development of resistance to treatment.
Interventions
- DRUG Docetaxel
- DRUG OGX-427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487786
The ClinicalTrials.gov registry entry for NCT00487786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00487786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00487786 about?
NCT00487786 is a clinical study titled "Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer". This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist. OGX-427 is an antisense product that inhibits expression of one of the heat shock proteins. Decreasing this heat shock protein (Hsp27) should result in do...
What is the current status of trial NCT00487786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2007-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00487786?
The interventions under investigation include: Docetaxel (DRUG), OGX-427 (DRUG).
Who is sponsoring clinical trial NCT00487786?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.